-

12:16:16 AM

AIM Stock News

AIM - AIM ImmunoTech Inc

05/19/22 8:00 AM

AMEX : AIM

conferences

AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the

RHEA-AI

neutral

05/18/22 8:00 AM

AMEX : AIM

covid-19

AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the

RHEA-AI

positive

05/16/22 7:05 AM

AMEX : AIM

earnings

AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update

- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer clinical studies as well as clinical

RHEA-AI

neutral

05/12/22 8:05 AM

AMEX : AIM

conferencescovid-19

AIM ImmunoTech to Participate in a Solve M.E. Signature Event: ‘Long COVID: Research, Policy, and Economic Impact’ on May 19, 2022

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the

RHEA-AI

neutral

04/21/22 8:05 AM

AMEX : AIM

AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies

Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen’s anti-tumor potential is demonstrated with checkpoint blockade therapies in human clinical studies for the treatment of triple-negative

RHEA-AI

neutral

04/12/22 7:47 AM

AMEX : AIM

clinical trial

AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer

- Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer - Company engages world-renowned CRO, Amarex Clinical Research LLC to conduct upcoming Phase 2 study - Company on track to

RHEA-AI

very positive

04/11/22 7:05 AM

AMEX : AIM

clinical trial

AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver

Primary endpoint of the study was met, evidenced by increased CD8a expression post-treatment (p=0.046) Data suggest that CKM regimen with Ampligen may be useful to enhance effectiveness of immunotherapies Data from clinical research conducted at Roswell Park Comprehensive Cancer Center presented in

RHEA-AI

neutral

04/11/22 7:05 AM

AMEX : AIM

clinical trial

AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer

Phase 1 study of metastatic triple-negative breast cancer using chemokine modulation (CKM) therapy, including Ampligen and pembrolizumab, successfully met primary endpoint Positive data from this proof-of-concept study demonstrate that short-term systemic CKM followed by pembrolizumab is

RHEA-AI

positive

03/31/22 4:05 PM

AMEX : AIM

earnings

AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

- Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen ® in multiple high-value indications - Company expected to continue advancing oncology-focused pipeline and well positioned to achieve multiple

RHEA-AI

neutral

03/28/22 7:35 AM

AMEX : AIM

AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next